Everything tagged "growth" across research, earnings, and macro.
192 articles
Chevron pairs integrated energy scale with visible production growth, strong free cash flow, and disciplined capital returns. The stock looks attractive for investors who want a high-quality oil major with medium-term upside and cycle resilience.
British American Tobacco is a medium-term Buy as combustibles keep generating cash while smokeless products, led by Velo, show real operating momentum. The stock looks reasonably valued with a fair value estimate of $68.
Credo Technology is emerging as a high-quality AI infrastructure winner, with explosive revenue growth, expanding margins, and a strong cash-rich balance sheet. The stock looks compelling operationally, but its premium valuation leaves less room for error.
UnitedHealth is showing a real earnings recovery, with Q2 2026 revenue of $112.0B and adjusted EPS of $6.38, but the stock still trades at a premium that leaves less room for execution mistakes.
Polestar showed real 2025 operating momentum, but the turnaround remains highly speculative amid heavy losses, negative cash flow, and going-concern risk. The stock is a Hold for investors willing to bet on product mix improvement and continued capital support.
STMicroelectronics is a Buy as revenue recovery, datacenter exposure, and MEMS expansion offset still-weak margins. The stock looks attractive for investors willing to wait for earnings repair.
Royal Caribbean is delivering record pricing, strong margin expansion, and double-digit revenue growth as its premium cruise platform keeps monetizing demand better than a typical cyclical operator.
JB Hunt posted a sharp 2Q26 rebound, led by intermodal and dedicated strength, but the stock already prices in much of the recovery. The result is a quality freight name with upside potential on pullbacks, not an obvious bargain.
State Street posted record 1Q26 AUC/A and AUM, with revenue and fee momentum improving across servicing, management, and FX. The stock looks like a disciplined Buy, though valuation already reflects much of the progress.
Citizens Financial Group is improving earnings power through margin expansion, stronger fee income, and a growing private bank. The stock still looks reasonably priced versus its rising earnings outlook.
Elevance Health is working through a Medicaid-driven margin reset, but Q2 results, raised guidance, and Carelon growth point to a resilient earnings recovery. The stock looks attractively valued for a large managed-care platform with scale, cash flow, and multiple growth levers.
HCA Healthcare delivered strong revenue, earnings, and cash flow growth despite a choppy quarter. The stock looks attractively valued, but its heavy debt load keeps the risk profile elevated.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator